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ABSTRACT
Aim The objective was to examine the prevalence of 
atherosclerotic cardiovascular disease (ASCVD) and its risk 
factors among patients with RA with diabetes mellitus (RA- 
DM) and patients with RA without diabetes mellitus (RAwoDM), 
and to evaluate lipid and blood pressure (BP) goal attainment 
in RA- DM and RAwoDM in primary and secondary prevention.
Methods The cohort was derived from the Survey of 
Cardiovascular Disease Risk Factors in Patients with 
Rheumatoid Arthritis from 53 centres/19 countries/3 
continents during 2014–2019. We evaluated the prevalence 
of cardiovascular disease (CVD) among RA- DM and 
RAwoDM. The study population was divided into those with 
and without ASCVD, and within these groups we compared 
risk factors and CVD preventive treatment between RA- DM 
and RAwoDM.
Results The study population comprised of 10 543 patients 
with RA, of whom 1381 (13%) had DM. ASCVD was present in 
26.7% in RA- DM compared with 11.6% RAwoDM (p<0.001). 
The proportion of patients with a diagnosis of hypertension, 
hyperlipidaemia and use of lipid- lowering or antihypertensive 
agents was higher among RA- DM than RAwoDM (p<0.001 for 
all). The majority of patients with ASCVD did not reach the lipid 
goal of low- density lipoprotein cholesterol <1.8 mmol/L. The 
lipid goal attainment was statistically and clinically significantly 
higher in RA- DM compared with RAwoDM both for patients 
with and without ASCVD. The systolic BP target of <140 mm 
Hg was reached by the majority of patients, and there were no 
statistically nor clinically significant differences in attainment 
of BP targets between RA- DM and RAwoDM.
Conclusion CVD preventive medication use and prevalence 
of ASCVD were higher in RA- DM than in RAwoDM, and lipid 
goals were also more frequently obtained in RA- DM. Lessons 
Key messages
What is already known about this subject?
 ► Clinical audits as the Survey of Cardiovascular 
Disease Risk Factors in Patients with Rheumatoid 
Arthritis can be applied to monitor data recording 
and management, measure clinical performance 
against guideline standards and inform appropri-
ate treatments to improve quality of care in routine 
practice.
 ► Both patients with rheumatoid arthritis (RA) and 
diabetes mellitus (DM) are associated with a dou-
bled risk of atherosclerotic cardiovascular disease 
(ASCVD) compared with the general population.
What does this study add?
 ► The diagnosis of hypertension and hyperlipidaemia 
was more common among patients with RA with DM 
than patients with RA without DM.
 ► Among patients with RA with DM, the prevalence of 
ASCVD was doubled compared with patients with RA 
without DM.
 ► Appropriate preventive cardiovascular disease (CVD) 
medication was more widely used and lipid targets 
more often obtained among patients with RA with 
DM compared with those without DM.
How might this impact on clinical practice or 
further developments?
 ► Lessons may be drawn from CVD prevention pro-
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may be learnt from CVD prevention programmes in DM to clinically benefit 
patients with RA .
INTRODUCTION
The prevalence of diabetes mellitus (DM) is approxi-
mately 9% of the world’s adult population, although 
there are large geographical variations from as low as 
2.5% (Republic of Moldovia) to 17% (Egypt).1 2 Further-
more, related to physical inactivity, unhealthy diet and 
obesity, the prevalence of diabetes is increasing in all 
age groups. The increased risk of cardiovascular disease 
(CVD) in patients with DM is well recognised, and there 
are specific guidelines for CVD prevention and risk factor 
management in such patients.3
Rheumatoid arthritis (RA) is the most common inflam-
matory rheumatic disease and is, like DM, associated 
with increased risk of CVD which is not fully explained 
by traditional CVD risk factors.4–6 This increased risk in 
patients with RA may be comparable to that of patients 
with DM.7 Prevention of atherosclerotic cardiovascular 
disease (ASCVD) in patients with RA is advocated both 
by the European League Against Rheumatism8 and other 
recent recommendations.4 Despite these efforts, ASCVD 
prevention in patients with RA was noted to be incom-
plete across the world in our international audit, Survey 
of Cardiovascular Disease Risk Factors in Patients with 
Rheumatoid Arthritis (SURF- RA),9 which was motivated 
by the clinical experience of inadequate CVD risk factor 
recording and CVD preventive medication use among 
patients with RA in many countries.
Patients with RA have a high comorbidity burden, and 
one of the most common comorbidities in RA is DM.10 
Compared with the general population, the prevalence 
of DM among patients with RA seems to be increased,11 
although there are conflicting reports.11–15 The increased 
risk of type 2 DM (T2DM) may be due to lifestyle- related 
factors such as physical inactivity and overweight, but also 
related to glucocorticoid use. Concomitant DM among 
patients with RA is a problem, because these patients 
have more ASCVD, depression, renal failure and hospital 
stays compared with patients with RA without DM.16 
In patients having both RA and DM, the risk of CVD is 
nearly tripled.7
Little is known about how DM affects ASCVD risk 
factor screening and management in patients with RA. 
Our objective was to examine the prevalence of ASCVD 
and its risk factors in patients with RA with and without 
DM, and to evaluate their lipid and blood pressure (BP) 
goal attainment in primary and secondary prevention 
based on the results from the large international audit 
SURF- RA.
METHODS
The data in SURF- RA were derived from already estab-
lished clinical cohorts, as well as from prospective 
recording in cardiology and rheumatology clinics, 
between 2014 and 2019. Patients aged >18 years with clin-
ically diagnosed RA were eligible for inclusion. Partici-
pating centres were divided into Western Europe, Eastern 
Europe, North America and Asia.
The following RA- related variables were recorded: rheu-
matoid factor and anti–citrullinated protein antibody posi-
tivity, inflammatory markers including C reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR), use of 
antirheumatic medication, as well as Disease Activity Score 
using 28 joints with ESR. CRP, ESR and lipid values were 
analysed according to each centre’s laboratory standards.
The presence of self- reported established CVDs, 
including coronary heart disease (CHD), stroke, periph-
eral arterial disease, atrial fibrillation and heart failure 
were registered by the physician in the data collection 
sheet. The following self- reported risk factors of CVD: 
smoking, physical activity, known diagnoses of hyperten-
sion, hyperlipidaemia and DM, as well as the most recent 
CVD risk factor measurements including BP, weight, 
height and waist circumference, were also recorded in 
the data collection sheet. Lipids, glucose and glycosylated 
haemoglobin A1c (HbA1c) were recorded if there were 
measurements within 1 year of examination. We lacked 
information on fasting status prior to lipid measurements, 
and both fasting and non- fasting lipid values may have 
been included. For general CVD risk screening, fasting 
status has been shown not to influence the prognostic 
value of blood lipids.17 The use of lipid- lowering agents, 
antihypertensive treatment and anti- diabetic medication 
was recorded. Glucose levels or HbA1c were not included 
in the DM definition, since the rationale was to identify 
only cases in which DM had been diagnosed and thus 
necessary preventive measures should have been taken.
The treatment goal of antihypertensive treatment 
was set at <140/90 mm Hg for patients without DM and 
<140/80 mm Hg for patients with DM according to the 
prevailing guidelines at the time of the survey.
At the time of the survey, the European Society of Cardi-
ology recommended that low- density lipoprotein choles-
terol (LDL- c) goal should be ≤2.5 mmol/L for patients at 
high risk of CVD and ≤1.8 mmol/L for patients with estab-
lished ASCVD.18
To reflect primary and secondary CVD prevention, 
comparisons of CVD risk factors and their management 
between patients with RA with and without DM were 
made separately for those with and without ASCVD 
(CHD, stroke or peripheral artery disease). To evaluate 
BP and LDL- c target attainment in primary prevention, 
we compared patients with RA with and without DM and 
without known ASCVD but who were using lipid- lowering 
or antihypertensive medications.
Summary statistics are presented as means or medians, 
with SD or IQR. To compare independent samples for 
continuous variables, we used Mann- Whitney U test, and for 
categorical variables, the χ2 test was applied. Data handling 
and statistical analyses were performed with R V.4.0.3 (R 
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RESULTS
Of the total SURF- RA cohort (n=14 504), we included 
cases with no missing data on age, sex, presence of DM 
or ASCVD. Cases with no recorded diagnosis of DM but 
recorded use of insulin or oral antidiabetic medication 
were excluded (n=83). The total study cohort comprised 
10 543 individuals from 19 countries across three conti-
nents. The proportion of patients from different world 
regions and ethnic groups is shown in table 1. RA- related 
factors and use of antirheumatic medication are shown in 
online supplemental table 1.
In most countries, 8%–15% of patients with RA had 
concomitant DM (figure 1). A total of 27% of the patients 
with RA with DM had ASCVD compared with 12% of 
patients with RA without DM (figure 2). CHD, stroke, 
peripheral artery disease, atrial fibrillation or heart failure 
were all more common among patients with RA with DM 
compared with patients with RA without DM. The total 
study population was divided into those with a diagnosis of 
ASCVD (n=1434) and those without (n=9109).
Patients with RA without ASCVD
Among the patients with RA without ASCVD, there were 
1012 cases who had concomitant DM and 8097 cases who 
did not. There were no differences in sex distribution, but 
patients with DM were slightly older than those without 
DM (table 1). The most common type of DM was T2DM 
(91.4%), while 49 patients (4.8%) had type 1 DM and 38 
(3.8%) had no record of DM type. Only 386 (38.1%) of 
patients with RA with DM had a measurement of HbA1c 
within 1 year before the survey inclusion (median (IQR) 
HbA1c 50 (42–61) mmol/mol) (table 2). Among the 
patients classified as not having DM, only 1179 (14.6%) 
had a measurement of HbA1c within the previous year, 
and a small proportion of them had elevated HbA1c as 
a sign of either impaired glucose regulation with HbA1c 
of 42–47 mmol/mol (n=100) or undiagnosed DM with 
HbA1c 48 mmol/mol or higher (n=17).
The proportion of patients with a diagnosis of hyperten-
sion, hyperlipidaemia, use of lipid- lowering or antihyper-
tensive agents was higher among patients with RA with DM 
than among those without (table 1). Patients with RA with 
DM had on average higher body mass index (BMI) and 
they were less often moderately or more than moderately 
physically active than those without DM (table 2). Patients 
with RA with DM were less frequently current smokers than 
patients with RA without DM (13% vs 17%).
Lipid measurements were available in 65% of the patients 
with DM and in 55% of patients without DM (table 2). Levels 
of LDL- c, high- density lipoprotein cholesterol (HDL- c) 
and total cholesterol were lower in the DM group, whereas 
triglycerides were higher compared with patients with RA 
without DM. Overall, patients with RA with DM and without 
ASCVD, but on lipid- lowering treatment for primary preven-
tion purposes had lower LDL- c compared with patients 
without DM, and this difference was statistically significant 
in subpopulations from Western Europe, Eastern Europe 
and North America (figure 3A).
BP measurements were available for 77% of the patients 
with RA with DM and 70% of the patients with RA without 
DM (table 2). Systolic BP was slightly higher among patients 
with RA with DM compared with those without (median 
difference 5 mm Hg), whereas diastolic BP was lower. We also 
compared systolic BP of patients with RA with and without 
DM receiving antihypertensive medication (figure 3C), and 
observed no significant differences.
Patients with RA with ASCVD
Of the patients with RA with ASCVD, 369 had concomitant 
DM and 1065 did not. There were no significant differ-
ences in age, sex or distribution across world regions in 
patients with ASCVD with and without DM (table 1). Of 
the patients with RA with DM, 352 (95.4%) had T2DM, 
12 (3.3%) had type 1 DM and 5 (1.4%) unknown type. 
Only 46.3% had a measurement of HbA1c within 1 year 
prior to survey inclusion (median (IQR) HbA1c of 49 
(42–58) mmol/mol) (table 2). Of the patients classified 
as not having DM, only 13.3% had a HbA1c measure-
ment within a year, and there were 21 cases with HbA1c 
of 42–47 mmol/mol and 3 cases with HbA1c above the 
diabetic threshold (48 mmol/mol or higher). Of ASCVD 
subtypes, CHD/stroke/peripheral artery disease was 
present among 61.0%/19.2%/51.2% of the patients with 
RA with DM versus 53.5%/22.2%/44.4% of the patients 
without DM, respectively (figure 2).
Proportions of patients with a diagnosis of hypertension, 
diagnosis of hyperlipidaemia and use of lipid- lowering or 
antihypertensive drugs including beta- blockers and ACE- 
inhibitors/angiotensin receptor blockers were higher 
for the patients with RA with ASCVD and DM compared 
with those without DM (table 1). Of note, of the patients 
with RA with ASCVD but no DM compared with patients 
with RA with ASCVD and DM, only 53% versus 72% 
respectively reported use of statins. Patients with RA with 
ASCVD and DM had higher BMI than patients without 
DM (table 2). There were no significant differences in 
physical activity level or smoking status.
Lipid measurements were available in 73% of patients 
with DM and in 65% of patients without DM with ASCVD 
(table 2). Comparable to the data on patients without 
ASCVD, levels of LDL- c, HDL- c and total cholesterol were 
lower whereas triglycerides were higher among those 
with DM compared with those without. Overall, neither 
the majority of patients with RA with ASCVD with DM 
nor without DM reached the treatment target of LDL- c 
<1.8 mmol/L in any of the world regions (figure 3B). 
On average, LDL- c levels were closest to the treatment 
target in North America and highest in Eastern Europe. 
Overall, patients with DM had lower LDL- c compared 
with patients without DM, and the difference was statisti-
cally significant in subpopulations from North America, 
Eastern and Western Europe (figure 3B).
BP measurements were available for 87% of the patients 
with DM and 83% of the patients without DM. Diastolic BP 
was slightly but statistically significantly lower among patients 
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the majority of patients across world regions, systolic BP was 
under the commonly used treatment target of 140 mm Hg 
(figure 3D). No consistent differences in systolic BP between 
patients with or without DM were noted.
DISCUSSION
To our knowledge, this is the first report comparing ASCVD 
risk factors, prevention and attainment of guideline- 
recommended treatment targets in patients with RA with 
and without DM. The major finding in this audit was that 
the treatment results for primary and secondary ASCVD 
prevention were superior in patients with RA with DM 
compared with patients with RA without DM. This was 
especially reflected in the higher proportion of patients 
with RA with ASCVD and DM reaching their lipid goals 
compared with patients with RA with ASCVD but without 
DM. Furthermore, screening of many CVD risk factors, 
especially hypercholesterolemia and DM or pre- diabetes, 
among patients with RA was inadequate and needs to 
be improved globally. Our findings highlight the impor-
tance of raising awareness of the increased risk of CVD in 
patients with RA, which can be achieved by information 
campaigns directed at patients and their spouses and all 
categories of healthcare personnel.
In this large audit of ASCVD and its risk factors in 
patients with RA, we have shown that patients with RA 
with DM have more than two times the frequency of 
ASCVD compared with patients with RA without DM. 
Figure 1 Percentage of patients with RA with concomitant diagnosis of diabetes mellitus by country. The number over the 
bars are %. RA, rheumatoid arthritis.
Figure 2 Prevalence of cardiovascular diseases (CVDs) among patients with rheumatoid arthritis with diabetes mellitus 
(n=1381) and without diabetes mellitus (n=9162). AF, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; CHD, 
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The increased risk of myocardial infarction in patients 
with RA has been known for decades and was reported 
by Holmqvist et al6 to be increased by 40% compared 
with the general population, despite the overall reduc-
tion in ASCVD since the 1970s. Furthermore, in line 
with our findings, a Danish nationwide cohort study 
including patients from 1997 to 2006 has reported a 
roughly doubled myocardial infarction incidence rate 
among patients with RA with DM compared with those 
without.7 We point out that our contemporary data imply 
that this increased ASCVD risk linked to the combination 
of having both RA and DM has not improved since then.
Despite the knowledge of the increased risk of ASCVD 
in patients with RA, their CVD risk factors often remain 
underdiagnosed and they receive poorer CVD preven-
tion than general population.19 20 We found that patients 
with RA with DM more often used lipid- lowering and 
antihypertensive medications compared with their coun-
terparts without DM, regardless if they had ASCVD or 
not. This may reflect the well- developed CVD preventive 
programmes in patients with DM. This patient group 
has specialised clinics, nurses, information materials and 
screening routines in many countries, although there 
may be variations in medical handling of DM across 
geographical regions. Despite the fact that statins are 
safe and effective among patients with RA,21 22 an alarm-
ingly low proportion (roughly 50%) of patients with RA 
without DM but with ASCVD used statins, and only a 
quarter reached the LDL- c target of ≤1.8 mmol/L. This 
could be related to clinical inertia, and warrants attention 
to initiation and adherence of lipid- lowering treatment. 
Also among the general population, CVD risk factors are 
strikingly common, and primary and secondary preven-
tion are often inadequate.23–25 A European 18- country 
observational study of patients using lipid- lowering agents 
showed that the 2016 LDL goals were attained by only 
22% and 45% of the very high- risk primary and secondary 
prevention patients, respectively.23 In the EUROASPIRE 
Figure 3 (A–D) Treatment target attainment for LDL- c and systolic BP among patients with RA with or without diabetes in 
primary prevention and secondary prevention by world regions. (A) LDL- c level in RA cases without ASCVD but with lipid- 
lowering agents for primary prevention. (B) LDL- c level in RA cases with ASCVD and in need of secondary prevention. (C) 
Systolic BP among patients with RA with antihypertensive drug treatment but no ASCVD. (D) BP among patients with RA with 
ASCVD. Red dashed lines depict commonly used treatment targets. Differences between patients with or without DM were 
compared with Mann- Whitney U test. The boxplots represent the distribution of measurements, with median as the black 
horizontal line in the middle of the box, IQR from 25th (Q1) to 75th (Q3) percentiles as the height of the box, and whiskers as 
Q1−1.5*IQR and Q3+1.5*IQR. Outliers are represented by grey dots. ASCVD, atherosclerotic cardiovascular disease; BP, blood 
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V study across 27 countries, 29% of patients with CHD 
reached LDL target of <1.8 mmol/L.24
The prevalence of diagnosed DM in patients with RA 
across countries varied mostly from 8% to 15%, although 
there were a few exceptions with DM prevalence as low as 
2%. Our findings are comparable to results from other 
RA cohorts from Italy15 (DM prevalence 13.6%) and 
the USA (10.4%).26 However, reflecting poor risk factor 
monitoring, HbA1c measurements were found in only 
less than one out of six patients with RA without DM, 
and thus we speculate that undiagnosed DM may be a 
considerable problem among patients with RA. Widdi-
field and colleagues have reported that only half of the 
individuals with RA were screened for CVD risk factors, 
including HbA1c.27 Importantly, an association between 
RA and undiagnosed DM has been reported by a German 
cross- sectional study.28 Of note, we found 20 patients 
without known diabetes but with diabetic HbA1c (range 
48.6–58.5 mmol/L, median 49.7), suggesting that HbA1c 
levels slightly over the diabetic threshold may not always 
receive attention.
The low frequency of lipid measurements in our survey 
reflects poor CVD risk factor management. This may be 
due to insufficient knowledge among health personnel,29 
and due to diffusion of responsibility for CVD risk eval-
uation between general practitioners, cardiologists and 
rheumatologists. The higher lipid goal attainment in 
patients with RA with DM may be related to the high 
focus on prevention of microvascular and macrovascular 
complications beyond glycaemic control in DM care, 
which is emphasised in DM treatment guidelines3 30 31 
and is well- implemented in primary care settings. Among 
patients with DM, CVD risk management may be taken 
care of by primary care physicians, internists or endocri-
nologists, whereas for patients with RA, CVD risk manage-
ment is mostly carried out by primary care physicians or 
rheumatologists.32 This may also explain why pharmaco-
logical secondary prevention, including lipid- lowering 
drugs, beta- blockers and ACE- inhibitors/angiotensin 
receptor blockers, was more frequent among the patients 
with RA with DM compared with those without. In addi-
tion, presence of DM may increase adherence to statins.33
The treatment goal of antihypertensive treatment 
was set at <140/90 mm Hg for patients without DM and 
<140/80 mm Hg for patients with DM according to the 
prevailing guidelines at the time of the survey, which is a 
modest approach compared with the most recent Euro-
pean guidelines on hypertension, which define different 
targets depending on age and side effects.34 Surprisingly, 
based on single measurements BP was well controlled in 
patients with RA. This is in contrast to patients with RA 
from a US report, where 40% had BP >140/90 mm Hg,14 
and to large populations with established CHD such as in 
Eurospire V survey (42% had BP >140/90 mm Hg) and in 
SURF- CHD survey (40% not at BP target).24 35
There are several limitations of a survey such as SURF- 
RA. First, the variations of the recorded prevalence of 
ASCVD risk factors across the three world continents may 
reflect the various settings for such risk factor recording. 
For example, the risk factors reported from North America 
were mostly extracted from primary care patient records, 
while SURF- RA centres in Western Europe were mostly 
rheumatology outpatient clinics and some cardiology 
outpatient clinics. Some of the data were extracted from 
pre- existing registries, which may explain the differences 
in missing data across the geographic regions. The rates 
of missing data on CVD risk factors highlight that, even 
in rheumatology centres with a focus on CVD prevention, 
the screening and recording of these crucial clinical vari-
ables are incomplete. This underlines the importance of 
increasing the awareness of this clinical field. The centres 
participating in the audit were either invited through 
the ATACC- RA network ( www. atacc- ra. com) or invited 
through conference contacts. Therefore, the represen-
tativeness of the cohorts in relation to nations, ethnic 
groups or geographic regions is not complete. In addi-
tion, the number of patients included from the various 
regions differed, with more patients recruited from 
North America and Western Europe. Another limitation 
is that we used the treatment goals of European recom-
mendations in evaluating treatment target attainment 
across world regions. Medication adherence was not 
evaluated and this may have influenced goal attainment. 
Participating centres did not share standardised instru-
ments for measurements, for example, same BP moni-
tors, height and weight measuring scales and laboratory 
measurements. Despite these limitations, clinical audits 
are valuable tools for improving clinical performance in 
implementing guideline- recommended procedures.
CONCLUSION
The use of CVD preventive medications and the presence 
of ASCVD was higher in patients with RA with DM than 
in patients with RA without DM. Lipid goals were also 
more frequently obtained in patients with RA with than 
without DM in both primary and secondary prevention. 
Based on this survey, special attention is needed to ensure 
that patients with RA with ASCVD reach their lipid goals. 
Data from the SURF- RA indicate that CVD prevention in 
DM is better implemented compared with patients with 
RA, and lessons may be drawn from the existing CVD 
prevention programmes in DM to enhance CVD preven-
tion among patients with RA.
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